Physician profile
Robert H Mcqueen
NPI 1780780882
$17,045.96
in general payments reported to CMS, 2019-2025
43 companies · $3,871 in 2025
The $3,871 reported for 2025 was more than what 90% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,304 · 2020: $1,266 · 2021: $1,148 · 2022: $3,621 · 2023: $1,959 · 2024: $3,876 · 2025: $3,871.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,501 · Travel and Lodging: $4,141 · Education: $64.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,501.10 |
| Travel and Lodging | $4,140.86 |
| Education | $64.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $7,749.53 | 2021-2025 | Micra, Selectsecure, Cobalt Dr Mri Surescan |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,295.72 | 2019-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $978.08 | 2019-2024 | Xarelto |
| Medtronic Vascular, INC. | $804.91 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $578.04 | 2021-2024 | Opsumit, Uptravi |
| Abbott Laboratories | $545.62 | 2020-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Ultreon |
| Novo Nordisk INC | $539.71 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $445.36 | 2021-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $425.84 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $394.29 | 2019-2024 | Farxiga |
| Esperion Therapeutics, INC. | $264.51 | 2020-2022 | |
| Boston Scientific Corporation | $233.30 | 2020-2025 | General - Catheter, General - Therapies, Bodyguardian |
| Baxter Healthcare | $213.47 | 2023-2024 | Hillrom - Carnation Ambulatory Monitor |
| E.R. Squibb & Sons, L.L.C. | $206.46 | 2020-2025 | Camzyos, Eliquis |
| Kiniksa Pharmaceuticals International, Plc | $163.30 | 2024 | Arcalyst |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Mcqueen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.